GLP-1 News

Oral Semaglutide Lowers Long-Term Heart Disease Risk

3 min read · Published 04-24-2026 · Sources cited to FDA / NIH / clinical trials

A new peer-reviewed study published in JAMA finds that oral semaglutide — the pill form of the active ingredient in Ozempic and Wegovy — can sustain long-term reductions in cardiovascular disease (CVD) risk factors. The findings are significant for the millions of people managing weight, blood sugar, and heart health with GLP-1 medications.

What the Study Found

According to the JAMA publication, oral semaglutide was associated with sustained, long-term reductions in cardiovascular disease risk factors. While injectable semaglutide has previously shown heart-protective benefits, this research adds meaningful evidence that the oral formulation may deliver similar lasting advantages for heart health.

Oral semaglutide — currently available as Rybelsus for type 2 diabetes — works through the same GLP-1 receptor pathway as its injectable counterparts, helping regulate blood sugar, reduce appetite, and influence cardiovascular markers such as blood pressure and cholesterol levels.

Why This Matters for GLP-1 Patients

For people who prefer not to use injectable medications, this research is encouraging. The convenience of a daily pill — rather than a weekly injection — has been a barrier consideration for some patients weighing GLP-1 therapy. Evidence that the oral version can produce durable cardiovascular benefits strengthens the case for it as a serious long-term treatment option, not just a stepping stone.

Heart disease remains the leading cause of death globally, and many people taking GLP-1 medications already carry elevated cardiovascular risk due to obesity or type 2 diabetes. Sustained risk factor reduction over time — rather than short-term improvement — is what clinicians and patients ultimately need to see.

Key takeaway: A JAMA study confirms that oral semaglutide can sustain long-term reductions in cardiovascular disease risk factors, offering important evidence that the pill form of semaglutide may protect heart health over time — not just while actively titrating the dose.

Important Caveats to Keep in Mind

The source material does not specify the trial name, study duration, patient population size, or exact percentages of risk reduction. Readers should look for the full JAMA publication to evaluate the strength of the evidence, including how "long-term" was defined and which specific CVD risk factors — such as HbA1c, blood pressure, LDL cholesterol, or body weight — were measured.

What to Watch Next

Regulatory agencies like the FDA have already approved injectable semaglutide for cardiovascular risk reduction in certain populations. Whether this new data on oral semaglutide accelerates any label expansion or new indications for Rybelsus will be worth monitoring. Expect further commentary from cardiologists and endocrinologists as the full JAMA findings are reviewed by the broader medical community.

Frequently Asked Questions

Oral semaglutide contains the same active ingredient as Ozempic and Wegovy but is taken as a daily pill rather than a weekly injection. It is currently marketed as Rybelsus and is approved for type 2 diabetes management.
Not necessarily. A published study showing sustained CVD risk factor reductions is an important step, but regulatory approval for a specific cardiovascular indication requires a formal review process by agencies like the FDA. Check with your doctor about current approved uses.
The source material confirms that CVD risk factors were reduced and sustained long-term, but does not specify which factors — such as blood pressure, LDL cholesterol, blood sugar, or body weight — were measured. The full JAMA article would contain those details.
No medication changes should be made based on a single news report. The best option for you depends on your specific health goals, medical history, insurance coverage, and how well your current treatment is working. Discuss any changes with your prescriber.
Many people taking GLP-1 medications have type 2 diabetes or obesity, both of which significantly raise cardiovascular risk. Long-term data showing sustained risk factor reduction — rather than only short-term improvements — helps doctors and patients feel confident these treatments provide durable heart health benefits over time.

As always, speak with your prescriber or a qualified healthcare professional before making any changes to your medication regimen. Individual health needs vary, and your doctor is best positioned to help you understand what this research means for your specific situation.

Sources
  • Peer-reviewed journal article, 'Oral Semaglutide Lowers Long-Term Heart Disease Risk,' JAMA, date not specified in source material.

Keep Reading

Headaches on Semaglutide: What Causes Them and When They StopSide Effects · 6 min readOzempic Vomiting: Why It Happens and How to Manage ItResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.